Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Impact of KRAS and TP53 Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With STK11-Mutated Advanced Non-Small-Cell Lung Cancer.

Bange E, Marmarelis ME, Hwang WT, Yang YX, Thompson JC, Rosenbaum J, Bauml JM, Ciunci C, Alley EW, Cohen RB, Langer CJ, Carpenter E, Aggarwal C.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00326. Epub 2019 May 10.

2.

Combination Immunotherapy in Non-small Cell Lung Cancer.

Marmarelis ME, Aggarwal C.

Curr Oncol Rep. 2018 May 8;20(7):55. doi: 10.1007/s11912-018-0697-7. Review.

PMID:
29740718
3.

Diagnostic Comparison of CT Scans and Colonoscopy for Immune-Related Colitis in Ipilimumab-Treated Advanced Melanoma Patients.

Garcia-Neuer M, Marmarelis ME, Jangi SR, Luke JJ, Ibrahim N, Davis M, Weinberg J, Donahue H, Bailey N, Hodi FS, Buchbinder EL, Ott PA.

Cancer Immunol Res. 2017 Apr;5(4):286-291. doi: 10.1158/2326-6066.CIR-16-0302.

4.

Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma.

Marmarelis ME, Davis MR, Sethi NS, Krajewksi KM, McKay RR, Choueiri TK, Ott PA.

J Immunother Cancer. 2016 Apr 19;4:26. doi: 10.1186/s40425-016-0129-x. eCollection 2016.

5.

Activity of the heat shock protein 90 inhibitor ganetespib in melanoma.

Wu X, Marmarelis ME, Hodi FS.

PLoS One. 2013;8(2):e56134. doi: 10.1371/journal.pone.0056134. Epub 2013 Feb 13.

Supplemental Content

Loading ...
Support Center